APLT241220P2500
- 0.15
- 0.000.00%
Applied Therapeutics Newsroom
Baird Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Positive Regulatory Outlook and Imminent PDUFA Date Justify Buy Rating for Applied Therapeutics
RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Applied Therapeutics (APLT) Gets a Buy From William Blair
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Leerink Partners Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Baird Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Applied Therapeutics Is Maintained at Outperform by Leerink Partners
Applied Therapeutics Analyst Ratings
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $11
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Raises Target Price to $11
Assessing Applied Therapeutics (APLT): Unveiling the Reasons Behind a Buy Rating
Leerink Partners Maintains Applied Therapeutics(APLT.US) With Buy Rating
William Blair Initiates Applied Therapeutics(APLT.US) With Buy Rating
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $8.00/Share From $7.00 by Citigroup
Applied Therapeutics Analyst Ratings
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Raises Target Price to $8
Optimistic Buy Rating for Applied Therapeutics Amid Positive Drug Approval Prospects